Yıl: 2020 Cilt: 50 Sayı: 1 Sayfa Aralığı: 239 - 247 Metin Dili: İngilizce DOI: 10.3906/sag-1909-46 İndeks Tarihi: 28-04-2020

Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial

Öz:
Background/aim: Carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections encountered in urology patients differentiate frominfections caused by other factors, both in respect to prophylaxis and treatment stage, and require a special approach. We aimed toanalyse the predisposing factors and the antibiotherapies for CR-KP infection outbreak in a tertiary urology clinic.Materials and methods: There were 75 patients in the CR-KP positive group (Group I) and 146 patients in the CR-KP negative group(Group II). Analysis of the predisposing factors for CR-KP infection and comparison of the reinfection rate and the antibiotherapies inthe 2 groups were the endpoints.Results: In the first group, age, comorbidity, previous antibiotic use, and nephrostomy tube rates were higher (P = 0.015, P = 0.001, P= 0.004, and P < 0.001, respectively). In the second group, open urological surgery rate, and the proportion of patients presenting withflank pain, lower urinary tract symptoms, and haematuria were higher (P = 0.029, P < 0.001, P < 0.001, and P = 0.007). In the first group,the proportion of patients treated with transurethral bladder tumour resection was higher, whereas, percutaneous nephrolithotomywas higher in the second group (P = 0.045 for both). While hospitalization and Foley catheterization duration were longer in the firstgroup (P < 0.001 for both), double J stent and nephrostomy duration were longer in the second group (P < 0.001 and P = 0.005). Meanleukocyte count at admission was higher in the first group (P < 0.001).Conclusion: Advanced age, comorbidities, previous antibiotic use, and prolonged Foley catheterization duration are predisposing factorsfor this infection in the urology department. Two-week administration of combination antibiotic regimens containing carbapenem wereeffective for the treatment of this infection.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases 2013; 13 (9): 785-796. Doi: 10.1016/S1473-3099(13)70190-7
  • 2. Zarakolu P, Eser OK, Aladag E, Al-Zahrani IA, Day KM et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013. Diagnostic Microbiology and Infectious Disease 2016; 85 (4): 466-470. doi: 10.1016/j. diagmicrobio.2016.05.012
  • 3. van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: Are we at the end of the road? Journal of Clinical Microbiology 2015; 53 (10): 3116- 7. doi: 10.1128/JCM.01399-15
  • 4. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A et al. Colistin resistance superimposed to endemic carbapenemresistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Eurosurveillance 2014; 19 (42). doi: 10.2807/1560-7917.es2014.19.42.20939
  • 5. van Duin D, Cober ED, Richter SS, Perez F, Cline M et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clinical Microbiology and Infection 2014; 20 (12): O1117-O1120. doi: 10.1111/1469-0691.12714
  • 6. Cai T, De Nunzio C, Salonia A, Pea F, Mazzei T et al. Urological infections due to multidrug-resistant bacteria: what we need to know? Urologia Journal 2016; 83 (1): 21-26. doi: 10.5301/ uro.5000123
  • 7. Samiolo A, Ardizzi E, Ardizzola A, Bianco O, De Luigi AR et al. The San Luigi Gonzaga Hospital experience: improving blood and urine culture preanalytical quality by shared protocols. Microbiologia Medica 2017; 32 (2). doi: 10.4081/ mm.2017.6602
  • 8. Bjerklund Johansen TE, Cek M, Naber K, Stratchounski L, Svendsen MV et al. Prevalence of hospital-acquired urinary tract infections in urology departments. European Urology 2007; 51 (4): 1100- 1111. doi: 10.1016/j.eururo.2006.08.012
  • 9. Totsika M, Moriel DG, Idris A, Rogers BA, Wurpel DJ et al. Uropathogenic Escherichia coli mediated urinary tract infection. Current Drug Targets 2012; 13 (11): 1386-1399. doi: 10.2174/138945012803530206
  • 10. Zalmanovici Trestioreanu A, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Library: Cochrane Reviews 2010 (10): CD007182. doi: 10.1002/14651858. CD007182.pub2
  • 11. Johansen TE. Nosocomially acquired urinary tract infections in urology departments. Why an international prevalence study is needed in urology. International Journal of Antimicrobial Agents 2004; 23 (Suppl. 1): S30-S34. doi: 10.1016/j.ijantimicag.2003.09.003.
  • 12. Nagai Y. About the J-GRID (Japan Initiative for Global Research Network on Infectious Diseases). Tropical Medicine and Health 2014; 42 (2 Suppl): 43-46. doi: 10.2149/tmh.2014-S06
  • 13. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant enterobacteriaceae infections. Open Forum Infectious Diseases 2015; 2 (2): ofv050. doi: 10.1093/ ofid/ofv050
  • 14. Evans R. European centre for disease prevention and control. Nursing Standard 2014; 29 (9): 30. doi: 10.7748/ns.29.9.30.s34
  • 15. Shevchenko OV, Mudrak DY, Skleenova EY, Kozyreva VK, Ilina EN et al. First detection of VIM-4 metallo-beta-lactamaseproducing Escherichia coli in Russia. Clinical Microbiology and Infection 2012; 18 (7): E214-E217. doi: 10.1111/j.1469- 0691.2012.03827.x
  • 16. Wailan AM, Paterson DL. The spread and acquisition of NDM-1: a multifactorial problem. Expert Review of Anti-infective Therapy 2014; 12 (1): 91-115. doi: 10.1586/14787210.2014.856756
  • 17. Kass EH, Schneiderman LJ. Entry of bacteria into the urinary tracts of patients with inlying catheters. The New England Journal of Medicine 1957; 256 (12): 556-557. doi: 10.1056/ NEJM195703212561206
  • 18. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE et al. Diagnosis, prevention, and treatment of catheterassociated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clinical Infectious Diseases 2010; 50 (5): 625-663. doi: 10.1086/650482
  • 19. Leuck AM, Wright D, Ellingson L, Kraemer L, Kuskowski MA et al. Complications of Foley catheters—is infection the greatest risk? Journal of Urology 2012; 187 (5): 1662-1666. doi: 10.1016/j.juro.2011.12.113
  • 20. Cullen IM, Manecksha RP, McCullagh E, Ahmad S, O’Kelly F et al. An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999- 2009. Irish Journal of Medical Science 2013; 182 (1): 81-89. doi: 10.1007/s11845-012-0834-5
  • 21. Medina-Polo J, Sopena-Sutil R, Benitez-Sala R, Lara-Isla A, Alonso-Isa M et al. Prospective study nalysing risk factors and characteristics of healthcare-associated infections in a Urology ward. Investigative and Clinical Urology 2017; 58 (1): 61-69. doi: 10.4111/icu.2017.58.1.61
  • 22. Smyth ET, McIlvenny G, Enstone JE, Emmerson AM, Humphreys H et al. Four country healthcare associated infection prevalence survey 2006: overview of the results. Journal of Hospital Infection 2008; 69 (3): 230-248. doi: 10.1016/j.jhin.2008.04.020
  • 23. Chenoweth CE, Gould CV, Saint S. Diagnosis, management, and prevention of catheter-associated urinary tract infections. Infectious Disease Clinics of North America 2014; 28 (1):105- 119. doi: 10.1016/j.idc.2013.09.002
  • 24. Wagenlehner FM, Wullt B, Perletti G. Antimicrobials in urogenital infections. International Journal of Antimicrobial Agents 2011; 38 Suppl.: 3-10. doi: 10.1016/j. ijantimicag.2011.09.004
  • 25. Nath S, Moussavi F, Abraham D, Landman D, Quale J. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy 2018; 73 (2): 431-436. doi: 10.1093/jac/dkx419
  • 26. Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. International Journal of Infectious Diseases 2017; 65: 1-3. doi: 10.1016/j.ijid.2017.09.017
  • 27. Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. The Lancet Infectious Diseases 2017; 17 (7): 726-734. doi: 10.1016/S1473- 3099(17)30228-1
  • 28. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clinical Infectious Diseases 2013; 56 (5): 697-700. doi: 10.1093/cid/cis969
  • 29. Dizbay M, Ozger HS, Karasahin O, Karasahin EF. Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam. Turkish Journal of Medical Sciences 2016; 46 (6): 1760-1764. doi:10.3906/sag-1506-157
  • 30. Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM et al. In vitro activity of Plazomicin against gramnegative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrobial Agents and Chemotherapy 2018; 62 (8). doi: 10.1128/AAC.00313-18
APA KIZILAY F, ALİYEV B, SIMSIR A, Kalemci S, KÖSE T, TAŞBAKAN M, PULLUKÇU H (2020). Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. , 239 - 247. 10.3906/sag-1909-46
Chicago KIZILAY Fuat,ALİYEV Bayram,SIMSIR ADNAN,Kalemci Serdar,KÖSE Timur,TAŞBAKAN Meltem,PULLUKÇU Hüsnü Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. (2020): 239 - 247. 10.3906/sag-1909-46
MLA KIZILAY Fuat,ALİYEV Bayram,SIMSIR ADNAN,Kalemci Serdar,KÖSE Timur,TAŞBAKAN Meltem,PULLUKÇU Hüsnü Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. , 2020, ss.239 - 247. 10.3906/sag-1909-46
AMA KIZILAY F,ALİYEV B,SIMSIR A,Kalemci S,KÖSE T,TAŞBAKAN M,PULLUKÇU H Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. . 2020; 239 - 247. 10.3906/sag-1909-46
Vancouver KIZILAY F,ALİYEV B,SIMSIR A,Kalemci S,KÖSE T,TAŞBAKAN M,PULLUKÇU H Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. . 2020; 239 - 247. 10.3906/sag-1909-46
IEEE KIZILAY F,ALİYEV B,SIMSIR A,Kalemci S,KÖSE T,TAŞBAKAN M,PULLUKÇU H "Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial." , ss.239 - 247, 2020. 10.3906/sag-1909-46
ISNAD KIZILAY, Fuat vd. "Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial". (2020), 239-247. https://doi.org/10.3906/sag-1909-46
APA KIZILAY F, ALİYEV B, SIMSIR A, Kalemci S, KÖSE T, TAŞBAKAN M, PULLUKÇU H (2020). Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. Turkish Journal of Medical Sciences, 50(1), 239 - 247. 10.3906/sag-1909-46
Chicago KIZILAY Fuat,ALİYEV Bayram,SIMSIR ADNAN,Kalemci Serdar,KÖSE Timur,TAŞBAKAN Meltem,PULLUKÇU Hüsnü Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. Turkish Journal of Medical Sciences 50, no.1 (2020): 239 - 247. 10.3906/sag-1909-46
MLA KIZILAY Fuat,ALİYEV Bayram,SIMSIR ADNAN,Kalemci Serdar,KÖSE Timur,TAŞBAKAN Meltem,PULLUKÇU Hüsnü Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. Turkish Journal of Medical Sciences, vol.50, no.1, 2020, ss.239 - 247. 10.3906/sag-1909-46
AMA KIZILAY F,ALİYEV B,SIMSIR A,Kalemci S,KÖSE T,TAŞBAKAN M,PULLUKÇU H Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. Turkish Journal of Medical Sciences. 2020; 50(1): 239 - 247. 10.3906/sag-1909-46
Vancouver KIZILAY F,ALİYEV B,SIMSIR A,Kalemci S,KÖSE T,TAŞBAKAN M,PULLUKÇU H Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. Turkish Journal of Medical Sciences. 2020; 50(1): 239 - 247. 10.3906/sag-1909-46
IEEE KIZILAY F,ALİYEV B,SIMSIR A,Kalemci S,KÖSE T,TAŞBAKAN M,PULLUKÇU H "Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial." Turkish Journal of Medical Sciences, 50, ss.239 - 247, 2020. 10.3906/sag-1909-46
ISNAD KIZILAY, Fuat vd. "Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial". Turkish Journal of Medical Sciences 50/1 (2020), 239-247. https://doi.org/10.3906/sag-1909-46